Search Results

Endologix PEVAR Trial Data Presented

January 28, 2013—Endologix, Inc. (Irvine, CA), announced that data from its prospective, multicenter, randomized clinical PEVAR trial  of a totally percutaneous approach (PEVAR) to endovascular abdominal aortic aneurysm repair (EVAR) were recently presented at two medical meetings.

Endologix Announces Publication of Data From PEVAR Randomized Trial

February 18, 2014—Endologix, Inc. (Irvine, CA) announced the publication of data from the first prospective, multicenter, randomized clinical trial of a totally percutaneous approach to endovascular abdominal aortic aneurysm repair (PEVAR) online ahead of print in the Journal of Vascular Surgery.  In this article, the investigators report on the randomized trial results comparing PEVAR using the Endologix sheath-based system delivered using a percutaneous approach (ie, the preclose technique) with the Perclose ProGlide suture-mediated closure system (Abbott Vascular, Santa Clara, CA) versus surgical-access EVAR (SEVAR).

FDA Approves Endologix System for PEVAR Indication

April 16, 2013—Endologix (Irvine, CA) announced that it has received US Food and Drug Administration (FDA) approval of its premarket approval supplement for a broadened indication for the company's 21-F profile and smaller endovascular aneurysm repair (EVAR) systems to include totally percutaneous EVAR (PEVAR) based upon the outcomes of the first prospective, multicenter, randomized clinical PEVAR trial.